Cargando…
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This pheno...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722775/ https://www.ncbi.nlm.nih.gov/pubmed/36483567 http://dx.doi.org/10.3389/fimmu.2022.1018786 |
_version_ | 1784844030492803072 |
---|---|
author | Nasiri, Fatemeh Kazemi, Mehrasa Mirarefin, Seyed Mohamad Javad Mahboubi Kancha, Maral Ahmadi Najafabadi, Milad Salem, Faeze Dashti Shokoohi, Setareh Evazi Bakhshi, Sahar Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria |
author_facet | Nasiri, Fatemeh Kazemi, Mehrasa Mirarefin, Seyed Mohamad Javad Mahboubi Kancha, Maral Ahmadi Najafabadi, Milad Salem, Faeze Dashti Shokoohi, Setareh Evazi Bakhshi, Sahar Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria |
author_sort | Nasiri, Fatemeh |
collection | PubMed |
description | Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine and HER2-specific antibody therapies. To date, surgery, radiotherapy, and systemic chemotherapy remain the principal therapy options for TNBC treatment. However, in numerous cases, these approaches either result in minimal clinical benefit or are nonfunctional, resulting in disease recurrence and poor prognosis. Nowadays, chimeric antigen receptor T cell (CAR-T) therapy is becoming more established as an option for the treatment of various types of hematologic malignancies. CAR-Ts are genetically engineered T lymphocytes that employ the body’s immune system mechanisms to selectively recognize cancer cells expressing tumor-associated antigens (TAAs) of interest and efficiently eliminate them. However, despite the clinical triumph of CAR-T therapy in hematologic neoplasms, CAR-T therapy of solid tumors, including TNBC, has been much more challenging. In this review, we will discuss the success of CAR-T therapy in hematological neoplasms and its caveats in solid tumors, and then we summarize the potential CAR-T targetable TAAs in TNBC studied in different investigational stages. |
format | Online Article Text |
id | pubmed-9722775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97227752022-12-07 CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil Nasiri, Fatemeh Kazemi, Mehrasa Mirarefin, Seyed Mohamad Javad Mahboubi Kancha, Maral Ahmadi Najafabadi, Milad Salem, Faeze Dashti Shokoohi, Setareh Evazi Bakhshi, Sahar Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria Front Immunol Immunology Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This phenomenon leaves no room for novel treatment approaches including endocrine and HER2-specific antibody therapies. To date, surgery, radiotherapy, and systemic chemotherapy remain the principal therapy options for TNBC treatment. However, in numerous cases, these approaches either result in minimal clinical benefit or are nonfunctional, resulting in disease recurrence and poor prognosis. Nowadays, chimeric antigen receptor T cell (CAR-T) therapy is becoming more established as an option for the treatment of various types of hematologic malignancies. CAR-Ts are genetically engineered T lymphocytes that employ the body’s immune system mechanisms to selectively recognize cancer cells expressing tumor-associated antigens (TAAs) of interest and efficiently eliminate them. However, despite the clinical triumph of CAR-T therapy in hematologic neoplasms, CAR-T therapy of solid tumors, including TNBC, has been much more challenging. In this review, we will discuss the success of CAR-T therapy in hematological neoplasms and its caveats in solid tumors, and then we summarize the potential CAR-T targetable TAAs in TNBC studied in different investigational stages. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9722775/ /pubmed/36483567 http://dx.doi.org/10.3389/fimmu.2022.1018786 Text en Copyright © 2022 Nasiri, Kazemi, Mirarefin, Mahboubi Kancha, Ahmadi Najafabadi, Salem, Dashti Shokoohi, Evazi Bakhshi, Safarzadeh Kozani and Safarzadeh Kozani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Nasiri, Fatemeh Kazemi, Mehrasa Mirarefin, Seyed Mohamad Javad Mahboubi Kancha, Maral Ahmadi Najafabadi, Milad Salem, Faeze Dashti Shokoohi, Setareh Evazi Bakhshi, Sahar Safarzadeh Kozani, Pouya Safarzadeh Kozani, Pooria CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil |
title | CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil |
title_full | CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil |
title_fullStr | CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil |
title_full_unstemmed | CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil |
title_short | CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil |
title_sort | car-t cell therapy in triple-negative breast cancer: hunting the invisible devil |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722775/ https://www.ncbi.nlm.nih.gov/pubmed/36483567 http://dx.doi.org/10.3389/fimmu.2022.1018786 |
work_keys_str_mv | AT nasirifatemeh cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT kazemimehrasa cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT mirarefinseyedmohamadjavad cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT mahboubikanchamaral cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT ahmadinajafabadimilad cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT salemfaeze cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT dashtishokoohisetareh cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT evazibakhshisahar cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT safarzadehkozanipouya cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil AT safarzadehkozanipooria cartcelltherapyintriplenegativebreastcancerhuntingtheinvisibledevil |